BioSpace News Archive

United Imaging, a global leader in producing advanced medical imaging and radiotherapy equipment, announced a series of commercially available and 510k pending technologies.

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”) announces the approval of its Investigational New Drug (IND) application by the United States Food and Drug Administration (US FDA) to evaluate its SAR-Bombesin product for identification and treatment of metastatic castrate-resistant prostate cancer (mCRPC).

Sanara MedTech Inc. announced today that Zach Fleming, the Company’s Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference in New York, New York on Wednesday, November 30, 2022 at 12:30 p.m. ET and will participate in a panel discussion at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference in Miami, Florida on Thursday, December 8, 2022 at 2:45 p.m. ET.

Arcutis Biotherapeutics, Inc. today announced the Company’s inaugural Environmental, Social, and Governance (ESG) report including a baseline of key performance metrics.

The Global Whole Exome Sequencing Market size is estimated to reach USD 525.74 million by 2030 from USD 219.89 million in 2019, delivering a CAGR of 11.6% through the forecast period.

Digital biology involves studying the fundamental computation of various biological processes, including gene regulatory systems and neural networks.

The global In Vitro Diagnostics market size was estimated at USD 111.68 billion in 2021 and is expected to surpass around USD 113.45 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 0.3% during the forecast period 2022 to 2030.

According to Nova one advisor, the global AI-based Clinical Trial Solutions For Patient Matching market size is expected to hit around USD 1.90 billion by 2030 from valued at USD 360.9 million in 2022 and growing at a CAGR of 27.7% from 2022 to 2030.

According to Latest Study, the U.S. Medical Device Outsourcing market size is expected to hit around USD 59.8 billion by 2030 from valued at USD 23.3 billion in 2021 and growing at a CAGR of 11.4% from 2022 to 2030.

According to Nova one advisor, the global DNA and Gene Cloning Services market was valued at USD 4.5 billion in 2021 and it is expected to hit around USD 11.5 billion by 2030 with a CAGR of 13.7% during the forecast period 2022 to 2030